$VRX (Valeant Pharmaceuticals International, Inc.)

$VRX {{ '2016-08-09T13:39:12+0000' | timeago}} • Webcast

David Risinger of Morgan Stanley asks whether $VRX has any list price increases assumed in 2H16 guidance. CFO Rob Rosiello said there is both a reflection of the discount and potential modest price increases that the company might take for the rest of 2016. He added that the launch costs are embedded in the company's budgets.

$VRX {{ '2017-10-10T14:50:38+0000' | timeago}} • Infographic

$VRX's progress towards paying down a huge debt of $5Bil before Feb 2018.

$VRX {{ '2017-09-29T17:50:36+0000' | timeago}} • Announcement

$VRX completed the sale of its iNova Pharmaceuticals business for $930MM in cash. The pharma company intends to use the net proceeds from the sale to repay term loan debt under its Senior Credit Facility.

$VRX {{ '2017-08-08T18:56:32+0000' | timeago}} • Webcast

$VRX cuts FY17 revenue guidance by $200MM to about $8.70-8.90Bil. This reflects the loss of approx. $170MM of Dendreon revenues. The overall reduced outlooks is mostly due to the revised expectation of the struggling Dermatology business.

$VRX {{ '2017-08-08T18:56:03+0000' | timeago}} • Webcast

During 2Q17, $VRX announced the use of cash on hand to redeem $500MM of outstanding senior notes due 2018. Since 1Q16, the company reduced total debt to $4.8Bil. $VRX expects to exceed the commitment of paying down $5Bil of debt from divestiture proceeds and free cash flow before February 2018.

$VRX {{ '2017-08-08T18:54:54+0000' | timeago}} • Webcast

$VRX's dermatology business continues to underperform. To address the challenges, the company has stabilized Derm ASP and have rebranded the business unit as Ortho Dermatologics during 2Q17. The company launched SILIQ on July. 27, 2017 as the new product under this business unit.

$VRX {{ '2017-08-08T14:16:40+0000' | timeago}} • Announcement

For FY17, $VRX lowered its revenue to about $8.70-8.90Bil from $8.90-9.10Bil. The company also plans to exceed commitment to pay down $5Bil in debt from divestiture proceeds and free cash flow before February 2018.

$VRX {{ '2017-08-08T14:07:13+0000' | timeago}} • Announcement

$VRX, Quebec-based drugmaker, reported 8% drop in its 2Q17 revenue to $2.23Bil. This decrease was mainly due to decline in volume and pricing of its U.S. Diversified Products segment. The company's net loss narrowed to $38MM, or $0.11 per share, compared to $302MM or $0.88 per share during 2Q16, mostly due to progress in debt reduction.

$VRX {{ '2017-08-08T12:03:05+0000' | timeago}} • Infographic

$VRX Valeant Pharmaceuticals International Earnings AlphaGraphics: Q2 2017 highlights

$VRX {{ '2017-07-17T14:04:54+0000' | timeago}} • Announcement

$VRX has entered into an agreement to sell its Obagi Medical Products business for $190MM in cash to Haitong International Zhonghua Finance Acquisition Fund I, L.P. The transaction is expected to close in second half of 2017. $VRX intends to use the proceeds from the sale to permanently repay term loan debt under its Senior Secured Credit Facility.

$VRX {{ '2017-07-10T13:27:06+0000' | timeago}} • Announcement

$VRX pays down $811MM of senior secured term loans using the net proceeds of the sale of Dendreon Pharmaceuticals LLC. The company has now reduced its debt by more than $4.3Bil since the end of 1Q16. $VRX still expects to pay down $5Bil in debt from divestiture proceeds and free cash flow within 18 months of August 2016.

$VRX {{ '2017-05-09T13:36:52+0000' | timeago}} • Webcast

$VRX commented that on the gastrointestinal franchise there were some challenges early in 1Q17. The company added that it has dealt with these challenges and added a primary care capability which was critical for the company.

$VRX {{ '2017-05-09T13:23:50+0000' | timeago}} • Webcast

$VRX stated that on a YoY basis in 1Q17, it has seen some brand price increase and was price positive both in the Branded RX and Bausch & Lomb International business. On a constant currency basis, Bausch & Lomb International also had volume growth, but the result was a negative FX.

$VRX {{ '2017-05-09T12:39:56+0000' | timeago}} • Infographic

$VRX Valeant Pharmaceuticals International Earnings AlphaGraphics: Q1 2017 highlights

$VRX {{ '2017-05-09T12:15:14+0000' | timeago}} • Announcement

As the drugmaker posted 1Q17 results, $VRX raised its FY17 guidance for non-GAAP EBITDA to $3.60-3.75Bil from previously expected $3.55-3.70Bil. The revised outlook reflects the impact of the sale of the CeraVe, AcneFree and AMBI skincare brands, but not the sale of the Dendreon business expected to close mid-year.

$VRX {{ '2017-05-09T12:12:01+0000' | timeago}} • Announcement

$VRX, whose stock longtime backer Bill Ackman unceremoniously dumped in March this year, delivered $954MM in cash flow from operations in 1Q17. Debt fell by $3.6Bil to $1.3Bil in the quarter, with Bausch Lomb/International segment revenues inching less than 1% up to $1.15Bil. U.S. Diversified Products segment revenues slipped 37% to $355MM.

$VRX {{ '2017-05-09T12:06:34+0000' | timeago}} • Announcement

Total revenues of struggling biotech giant $VRX slipped 11% to $2.1Bil in 1Q17, as a one-time tax benefit of $908MM pushed Valeant to profit with a net attributable income of $628MM from last year's loss of $374MM. Earnings in the quarter were $1.79 per diluted share, compared to the year-ago loss of $1.08 per share.

$VRX {{ '2017-02-28T14:47:35+0000' | timeago}} • Webcast

$VRX said that on the Xifaxan litigation, the company does not comment on the ongoing litigations but expects a trial in 2018. $VRX believes it has got strong intellectual property (IP) on the product & its patents run through 2029. Therefore, the company feels good about the number of patents it has relative to the IP associated with the product.

$VRX {{ '2017-02-28T14:00:42+0000' | timeago}} • Webcast

$VRX said it is looking for low single digit growth in GI business in 2017, before moving to high single digit growth in 2018 and beyond. Additionally, the diversified segment, which is projected to decline 7-10% in 2017 vs. 2016, is expected to still face above average declines in 2018.

$VRX {{ '2017-02-28T13:49:38+0000' | timeago}} • Webcast

$VRX generated under $2.1Bil of net cash from operating activities in calendar year 2016 and reduced total debt by about $1.2Bil. The company ended FY16 with $30.1Bil in principle amount of funded debt outstanding and cash on hand of $542MM. $VRX currently has $875MM drawn on its $1.5Bil revolver.

$VRX {{ '2017-02-28T13:40:48+0000' | timeago}} • Infographic

$VRX Valeant Pharmaceuticals International Earnings AlphaGraphics: Q4 2016 Highlights

Recent Transcripts

CLSN (Celsion Corporation)
Tuesday, August 15 2017 - 3:00pm
MYL (Mylan N.V.)
Wednesday, August 9 2017 - 2:00pm
IPXL (Impax Laboratories Inc.)
Wednesday, August 9 2017 - 12:30pm
CCXI (ChemoCentryx, Inc.)
Tuesday, August 8 2017 - 9:00pm
OMER (Omeros Corporation)
Tuesday, August 8 2017 - 8:30pm
DRRX (DURECT Corporation)
Tuesday, August 8 2017 - 8:30pm
NVAX (Novavax, Inc.)
Tuesday, August 8 2017 - 8:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, August 8 2017 - 12:00pm
IRIX (IRIDEX Corporation)
Thursday, August 3 2017 - 9:00pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, August 3 2017 - 12:30pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
TEVA (Teva Pharmaceutical Industries Limited)
Thursday, August 3 2017 - 11:30am
MASI (Masimo Corporation)
Wednesday, August 2 2017 - 8:30pm
AMRN (Amarin Corporation plc)
Wednesday, August 2 2017 - 12:00pm
KTWO (K2M Group Holdings, Inc.)
Tuesday, August 1 2017 - 9:00pm
ABBV (AbbVie Inc.)
Friday, July 28 2017 - 1:00pm
BMY (Bristol-Myers Squibb Company)
Thursday, July 27 2017 - 2:30pm
PG (The Procter & Gamble Company)
Thursday, July 27 2017 - 12:30pm
GILD (Gilead Sciences Inc.)
Wednesday, July 26 2017 - 8:30pm
AMGN (Amgen Inc)
Tuesday, July 25 2017 - 9:00pm

AlphaGraphics you may like